Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.61 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4113212 | 0.87 | CYP4F2 (0.76) | CYP4F2CYP4A11KMT2AMAPTALDH1A1 | |
| SCHEMBL26502663 | 0.85 | CYP4F2 (0.58) | CYP4F2CYP4A11KMT2AMAPTALDH1A1 | |
| SCHEMBL479979 | 0.84 | CYP4F2 (0.61) | CYP4F2CYP4A11KMT2AMAPTALDH1A1 | |
| SCHEMBL1198228 | 0.84 | LOXL2 (0.63) | CYP4F2CYP4A11KMT2AMAPTALDH1A1 | |
| SCHEMBL4613929 | 0.83 | CYP4F2 (0.66) | CYP4F2CYP4A11KMT2AMAPTALDH1A1 | |
| SCHEMBL23582497 | 0.82 | CYP4F2 (0.59) | CYP4F2CYP4A11MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL968517 | 0.82 | CYP4F2 (0.59) | CYP4F2CYP4A11KMT2AMAPTALDH1A1 | |
| SCHEMBL168858 | 0.81 | KMT2A (0.59) | CYP4F2CYP4A11KMT2AMAPTALDH1A1 | |
| SCHEMBL8776608 | 0.81 | CYP4F2 (0.62) | CYP4F2CYP4A11KMT2AMAPTALDH1A1 | |
| SCHEMBL5042255 | 0.81 | KMT2A (0.67) | CYP4F2CYP4A11KMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3615525-B1 | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | SENTINEL ONCOLOGY LTD (GB) | 2024-12-25 | — | — | EP | disclosed |
| US-11884656-B2 | Pyrrole derivatives as PLK1 inhibitors | SENTINEL ONCOLOGY LIMITED (GB) | 2024-01-30 | — | — | US | disclosed |
| US-20230279010-A1 | PROCESSES FOR PREPARING MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-09-07 | — | — | US | disclosed |
| US-20230174483-A1 | INDIRUBIN DERIVATIVES, AND USES THEREOF | CITY OF HOPE (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174483-A1 | INDIRUBIN DERIVATIVES, AND USES THEREOF | CITY OF HOPE (US) | 2023-06-08 | — | — | US | disclosed |
| CN-110573503-B | Pyrrole derivatives as PLK1 inhibitors | 圣提内尔肿瘤学有限公司 | 2023-03-17 | — | — | CN | disclosed |
| US-11524937-B2 | Indirubin derivatives, and uses thereof | CITY OF HOPE (US) | 2022-12-13 | — | — | US | disclosed |
| US-20220135552-A1 | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2022-05-05 | — | — | US | disclosed |
| US-20220135552-A1 | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2022-05-05 | — | — | US | disclosed |
| US-11208405-B2 | Pyrrole derivatives as PLK1 inhibitors | SENTINEL ONCOLOGY LIMITED (GB) | 2021-12-28 | — | — | US | disclosed |
| WO-2013093484-A1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-06-27 | — | — | WO | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20100081799-A1 | Chelating Agent | TECHNISCHE UNIVERSITAT MUNCHEN (DE) | 2010-04-01 | — | — | US | disclosed |
| CN-101605768-A | Sequestrant | UNIV MUENCHEN TECH (DE) | 2009-12-16 | — | — | CN | disclosed |
| EP-2099776-A1 | CHELATING AGENT | Technische Universität München (DE) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008068516-A1 | CHELATING AGENT | Technische Universität München (DE) | 2008-06-12 | — | — | WO | disclosed |
| US-5922717-A | ANTICOAGULANTS | DR. KARL THOMAE GMBH (DE) | 1999-07-13 | — | — | US | disclosed |
| CN-1183770-A | Piperazine derivatives, medicaments containing these compounds, their use and processes for their preparation | THOMAE GMBH DR K (DE) | 1998-06-03 | — | — | CN | disclosed |
| US-5700801-A | ANTIINFLAMMATORY AGENTS, BONE DISORDERS | KARL THOMAE, GMBH (DE) | 1997-12-23 | — | — | US | disclosed |
| CN-1131665-A | Piperazine derivatives, medicaments comprising these compounds, their use and processes for their preparation | THOMAE GMBH DR K (DE) | 1996-09-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174483-A1 | INDIRUBIN DERIVATIVES, AND USES THEREOF | HCCS, ABL1, MAP3K7 | CYP4F2 2830/4885CYP4A11 1460/4885KMT2A 1407/4885 |
| US-11524937-B2 | Indirubin derivatives, and uses thereof | HCCS, ABL1, MAP3K7 | CYP4F2 2830/4885CYP4A11 1460/4885KMT2A 1407/4885 |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | CYP4F2 2810/4885CYP4A11 1793/4885KMT2A 3548/4885 |
| US-11884656-B2 | Pyrrole derivatives as PLK1 inhibitors | PLK1, CDK1, AURKC | CYP4F2 3579/4885CYP4A11 3153/4885KMT2A 1988/4885 |
| US-20230279010-A1 | PROCESSES FOR PREPARING MODULATORS OF ALPHA-1 ANTITRYPSIN | SERPINA2, SERPINC1, SERPINE1 | CYP4F2 3319/4885CYP4A11 1481/4885KMT2A 4507/4885 |
| US-20100081799-A1 | Chelating Agent | HRH3, C3AR1, H1-3 | CYP4F2 953/4885CYP4A11 3093/4885KMT2A 365/4885 |
| US-20220135552-A1 | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | PLK1, CDK1, AURKC | CYP4F2 3579/4885CYP4A11 3153/4885KMT2A 1988/4885 |
| US-11208405-B2 | Pyrrole derivatives as PLK1 inhibitors | PLK1, CDK1, AURKC | CYP4F2 3527/4885CYP4A11 3027/4885KMT2A 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.